Independent Medical Education (IME) Program supports medical education providers’ work on hereditary angioedema and severe hypertriglyceridemia to improve clinical knowledge and care.
Funder: Ionis Pharmaceuticals
Due Dates: At least 60 calendar days before program/event start (IME requests)
Funding Amounts: Requests may receive less than the amount requested; multiple potential supporters preferred
Summary: Supports independent medical education in the United States on hereditary angioedema and severe hypertriglyceridemia to improve clinical knowledge and care.
Key Information: Activity organizers must retain sole control of the agenda, content, and faculty, independent of industry influence.
Ionis Pharmaceuticals’ Independent Medical Education (IME) Program supports targeted, high-quality accredited and non-accredited education that advances clinical care through improved disease awareness, clinical knowledge, and multidisciplinary management. The program accepts requests for medical education in the United States focused on hereditary angioedema (HAE) and severe hypertriglyceridemia (sHTG).
HAE priorities emphasize unmet patient needs, disease control, long-term prophylaxis, individualized treatment selection, and shared decision making. sHTG priorities address acute pancreatitis risk and prevention, diagnosis, pathophysiology, clinical management, and disease burden. Education must be evidence-based, fair-balanced, unbiased, and independent of industry influence. Ionis does not provide guidance to IME providers on their educational activities.